Novel coronavirus detection composition, kit and library construction method
By designing 96 pairs of stacked PCR amplification primers and combining high coverage depth sequencing technology, the problem of reduced detection sensitivity of mutant strains in the whole genome detection of novel coronavirus was solved, and high accuracy of SARS-CoV-2 genome was achieved and efficient detection.
Patent Information
- Application Number
- CN202311394161.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-10-26
- Publication Date
- 2024-11-22
AI Technical Summary
The existing SARS-CoV-2 whole genome sequencing method reduces detection sensitivity and loses amplicons when facing the ever-mutated virus strain, especially the novel variant EG.5 and its progeny strains and BA.2.86. and reduced coverage leads to inaccurate lineage analysis results, difficulty in tracking gene diversity and monitoring specific mutations.
96 pairs of tiled PCR amplification primers were designed, and the sequencing linker was designed for SARS-CoV-2 whole genome sequence was combined with Illumina second-generation sequencing and QiCan third-generation portable nanopore gene sequencing to achieve all amplified regions. High coverage depth improves detection accuracy and efficiency and reduces background noise.
High coverage detection of SARS-CoV-2 genome is achieved, reducing the demand for sample starting volume, improving the sequencing success rate, and ensuring accurate detection and mutation analysis of new variant strains.
Smart Images

Figure CN118995997A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of molecular detection, and specifically, to a novel coronavirus whole genome detection composition, a kit and a library construction method. Background Art
[0003] Whole genome sequencing is essential for COVID-19 surveillance to understand the viral mutation rate and transmission dynamics of new SARS-CoV-2 variants, and to provide information for the control of SARS-CoV-2 transmission and the implementation of preventive measures. At the same time, tracking the genetic diversity of SARS-CoV-2 variants will help study the pathogenesis of the disease, while identifying sites on the genome that may reduce the effectiveness of vaccines and drug treatments, ultimately providing information for the design of future therapies. Currently, many methods have been used for SARS-CoV-2 whole genome sequencing, including metagenomic sequencing and targeted sequencing. Metagenomic sequencing, also known as shotgun gene sequencing, is widely used for pathogen detection and analysis of microbial diversity in environmental / clinical samples. Its advantage is that it does not require prior knowledge of the viral genome, which is conducive to the discovery of new viruses; its disadvantage is that it is easily affected by host and other microbial nucleic acids, and the detection sensitivity is reduced. Targeted sequencing is mainly divided into two types: amplicon sequencing based on multiple primer PCR amplification and probe capture sequencing based on probe hybridization. Probe capture sequencing first constructs a conventional metagenomic library for the sample, then uses artificially synthesized oligonucleotide probes containing a series of known viral sequences to hybridize and enrich the library viral sequences, and finally PCR amplifies the enriched library and then sequences it on the machine. This method has high sensitivity, and the detection specificity depends on the type and number of probes, but it is expensive, complicated to operate, and extremely time-consuming, and has higher background noise. Multiplex PCR amplicon sequencing is currently the most widely used sequencing method. Dozens of pairs of specific primers covering the entire SARS-CoV-2 genome are combined into two primer pools to amplify the viral genome separately, and then the amplified products are sequenced using high-throughput sequencing methods. This method is simple to operate and has high sensitivity, and only a small amount of data is needed to obtain the entire viral genome.
[0004] As COVID-19 spreads around the world, SARS-CoV-2 continues to mutate, showing the characteristics of a gradual increase in nucleotide mutation sites and differential distribution of mutations in the genome. The generation of new variants is determined by a combination of multiple mutations, among which mutations occurring in the gene encoding the spike S protein are the main ones. In addition to XBB.1.5 and XBB.1.16, WHO has tracked down a new variant EG.5 and its progeny strains with unique mutations and enhanced transmissibility, and defined them as variants of concern (VOC) on August 9, 2023. They are the progeny lineage of XBB.1.9.2. Compared with XBB.1.9.2 and XBB.1.5, the S protein region carries the F456L mutation, and the progeny EG.5.1 also exhibits the Q52H mutation. In addition, on August 17, 2023, WHO included a new coronavirus variant BA.2.86 in the monitoring variants (VUM). It is reported that BA.2.86 carries a large number (>30) of spike gene mutations. If these mutations occur within the primer binding sites of multiplex PCR amplification, they can prevent primer annealing and lead to loss of amplicons and reduced coverage of critical regions, thereby producing low-quality genomes with N insertions in the missing amplicon regions, causing inaccurate lineage analysis results and making it challenging to monitor lineage-specific mutations in VOCs.
[0005] In order to ensure the accuracy of amplicon sequencing of the evolving SARS-CoV-2 variants, it is necessary to design multiple PCR amplification reaction primers based on the latest variants. Therefore, a product that can detect the most complete new coronavirus genome is needed in this field. Summary of the invention
[0006] In view of this, the first aspect of the present invention is to provide a composition for whole genome detection of a novel coronavirus, the composition comprising:
[0007] Oligonucleotides as shown in SEQ ID NOs: 1-192.
[0008] Furthermore, the composition further comprises a primer pair designed according to the sequencing adapter.
[0009] The above-mentioned design based on sequencing adapters (ie, the second round PCR amplification primer pair) can be determined by those skilled in the art according to conventional methods in the art according to different sequencing platforms.
[0010] On the one hand, the composition of the present invention can be used to construct a new coronavirus whole genome gene library, and on the other hand, it can be used to improve the success rate of new coronavirus sequencing.
[0011] Furthermore, the primer set includes 96 pairs of shingled PCR amplification primers designed for the whole genome sequence of the SARS-CoV-2 variant, including a first primer set and a second primer set. The first primer set includes 48 pairs of amplification primers, with specific sequences such as SEQ ID No. 1-96; the second primer set includes 48 pairs of amplification primers, with specific sequences such as SEQ ID No. 97-192.
[0012] Considering the balance of different multiplex PCR amplification products, strain NC_045512 was used as the reference genome, and it was compared with SARS-CoV-2 Alpha, Beta, Delta, Gamma, and multiple new Omicron variant sequences imported from abroad from January to August 2023. 96 pairs of shingled PCR amplification primers were designed for the conservative regions of the compared sequences, and the primer pool for multiple RCR amplification was updated to avoid the loss of amplicons, increase the amplification efficiency, and the amplification product of each pair of amplification primers was about 400bp. There is an overlap of about 100bp between the primer amplification regions adjacent to the amplification primers in the detection primer set to completely cover the viral genome. The present invention achieves a coverage depth of >100 times and >30 times for all amplification regions in the second-generation sequencing of Illumina and the third-generation portable nanopore gene sequencing developed by Qi Carbon, respectively.
[0013] On the one hand, the high specificity of the first round of PCR ensures efficient utilization of the template, and the second and / or third generation sequencing (i.e., the second round of PCR) increases the library sequence concentration. Therefore, when using the composition of the present invention for mutation detection, the sample starting amount is only 10 ng.
[0014] In a second aspect, a method for preparing a novel coronavirus whole genome detection kit using the composition of the present invention is provided.
[0015] In a third aspect, the present invention provides a kit for whole genome detection of the novel coronavirus, the kit comprising: the composition as described above.
[0016] Furthermore, the above-mentioned kit also contains reagents required for extraction, reagents required for amplification and reagents required for sequencing.
[0017] The reagents required for extraction refer to the reagents required to extract the desired nucleic acid from the sample, such as commercial nucleic acid extraction kits (Daan paraffin genomic DNA extraction kit, Daan blood genomic DNA extraction kit, etc. can be used).
[0018] The reagents required for amplification include reagents required for the first round of PCR amplification, such as polymerase, buffer, dNTP, etc.
[0019] The polymerase is preferably a polymerase suitable for long fragment amplification, for example, FastStart High Fidelity Enzyme hot start enzyme.
[0020] The reagents required for sequencing include fragmentation reagents, fragment purification reagents, end repair and adenine addition reagents, adapter ligation reagents and reagents required for sequencing (second round of PCR amplification).
[0021] The fragmentation reagent is a reagent that can fragment the amplification product (ie, amplicon). In a specific embodiment, the fragmentation reagent is a double-stranded DNA fragmentase.
[0022] The fragment purification reagent is a reagent that can select fragments of specific lengths according to specific needs. In a specific embodiment, the fragment purification reagent is magnetic beads.
[0023] End repair and adenine addition reagents include: dNTP, T4 PNK, T4 DNA polymerase, Klenow fragment, etc.
[0024] The linker connection reagent includes a linker and a DNA ligase. The linker can be determined by conventional methods according to different sequencing platforms. In a specific embodiment, the linker sequence is: the forward linker is GATCGGAAGAGCACACGTCTGAACTCCAGTCAC, and the reverse linker is TACACTCTTTCCCTACACGACGCTCTTCCGATCT, and in a specific embodiment, the DNA ligase is T4 ligase.
[0025] The reagents required for the second round of PCR amplification include: buffer, MgSO4, DNA polymerase, and primer pairs required for amplification. In a specific embodiment, the primer pairs required for amplification are a linker forward primer, such as AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT; and a linker negative primer, such as CAAGCAGAAGACGGCATACGAGATNNNNNNNNGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT.
[0026] In a fourth aspect, the present invention provides a method for constructing a novel coronavirus pre-genomic gene library, the method comprising:
[0027] 1) amplifying a sample using the composition or kit of the present invention to obtain an amplicon;
[0028] 2) fragmenting the amplicon;
[0029] 3) Purify the fragments, perform end repair and add adenylate;
[0030] 4) connecting the joints; and
[0031] 5) One or both of the second generation sequencing and the third generation sequencing.
[0032] The samples applicable to the test are not limited to sputum, alveolar lavage fluid, pharyngeal secretions and blood.
[0033] In a specific embodiment, the first round of PCR amplification in step 1) is performed by dividing the above composition or kit into two tubes.
[0034] In a specific embodiment, the fragmentation in step 2) can be chemical fragmentation, and the chemical fragmentation is the use of chemical substances that can fragment DNA. In a specific embodiment, the chemical fragmentation is enzymatic fragmentation, and in a specific embodiment, the enzyme used for the enzymatic fragmentation is dsDNA fragmentase.
[0035] In a specific embodiment, the fragmentation in step 2) can be physical fragmentation, which is to use physical means to fragment DNA. In a specific embodiment, the physical fragmentation is physical ultrasonic shearing.
[0036] In a specific embodiment, the library is fragmented into fragments with a main peak of 300 bp and a range of 200 to 400 bp. The above fragment range is the most suitable sequencing length and can better be compatible with sequencing modes of different lengths.
[0037] In a specific embodiment, the purification of fragments in step 3) can be performed by adjusting the amount of magnetic bead solution. The source of the magnetic beads is not particularly limited and any conventional commercial product in the art can be used.
[0038] In a specific embodiment, the magnetic beads are selected from Beckman Agencurt AMPure XP (specification 450 ml, No. A63882, purchased from Beckman Company).
[0039] In a specific embodiment, the end repair and adenine addition in step 3) are performed, including but not limited to, using dNTPs, T4 PNK, T4 DNA polymerase, and Klenow fragment.
[0040] In a specific embodiment, step 4) is performed including but not limited to using an adapter and a DNA ligase.
[0041] In a specific embodiment, step 5) is performed including but not limited to using a buffer, MgSO4, a DNA polymerase, and a primer pair required for amplification.
[0042] In the fifth aspect, the present invention provides a new coronavirus whole genome gene library obtained according to any of the methods described above.
[0043] Furthermore, after the library construction is completed, the library is sequenced for mutation detection.
[0044] In a specific embodiment, the sequencing is second generation sequencing. In a specific embodiment, the sequencing platform of the second generation sequencing is not limited to Illumina, ABI-SOLiD or Ion Torrent related sequencing platform sequencing, and the sequencing kit read length is not limited to 75 cycles, 150 cycles, and is applicable to various types of read length sequencing kits currently on the market.
[0045] The back-end of the present invention adopts a method of breaking and connecting the library to adapt to different read length sequencing kits. For conventional PCR amplification library construction, the read length of the sequencing kit selected must not be shorter than the longest amplicon length. The library constructed by the method described in the present invention has better compatibility with the sequencing platform and sequencing kit, and is also convenient for carrying other libraries for sequencing, thereby reducing sequencing costs. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1 This is the sequencing result diagram of sample 1;
[0047] Figure 2 This is the sequencing result diagram of sample 2;
[0048] Figure 3 This is the sequencing result diagram of sample 3;
[0049] Figure 4 This is the sequencing result diagram of sample 4;
[0050] Figure 5 and Figure 6 This is a graph showing the results of the third generation sequencing of clinical samples detected by the composition of the present invention;
[0051] Figure 7 and Figure 8 The sequencing result diagrams of sample S5 detected according to Example 6 and Comparative Example 1 are shown respectively;
[0052] Fig. 9 The primer pair sequences used in Comparative Example 1 are shown. DETAILED DESCRIPTION
[0053] The present invention will be described in detail below in conjunction with specific embodiments and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific embodiments and examples are used to illustrate the present invention, rather than to limit the present invention.
[0054] Example 1, primer design
[0055] Multiple primers were designed for the full length of the SARS-CoV-2 gene, and all 96 pairs of primers are shown in Table 1.
[0056] Table 1. Specific amplification primer pairs
[0057]
[0058]
[0059]
[0060]
[0061] Example 2: Whole genome capture
[0062] (1) RNA extraction: The RNA of the new coronavirus is extracted using the Daan Nucleic Acid Extraction or Purification Kit. The magnetic bead binding solution contains a powerful protein denaturant that can quickly dissolve proteins and dissociate nucleic acids. In its presence, the released nucleic acid components can bind to the magnetic beads, and then the proteins, inorganic salt ions and many organic impurities are removed by the magnetic bead washing solution. The pure nucleic acid is then eluted with the eluent. The extracted viral RNA is tested by fluorescent quantitative PCR, and nucleic acid samples with a Ct value below 35 can continue with subsequent operations. If the virus is not tested directly after extraction, it can also be stored at -80°C for future use, but repeated freezing and thawing should be avoided.
[0063] (2) Reverse transcription: cDNA was prepared using the LunaScript RT SuperMix Kit from NEB, and the reaction system was:
[0064]
[0065] Note: Viral RNA input values from clinical samples should be between Ct 21-27. If the Ct is between 12-15, dilute the sample 100-fold, and if it is between 15-18, dilute it 10-fold, which helps reduce the possibility of PCR inhibition. Pay attention to prevent pre-PCR contamination.
[0066] Set up the following program on the thermal cycler:
[0067] 25℃ 2min 55℃ 10min 95℃ 1min 4℃ Hold
[0068] (3) Preparation of primer pool: The 96 pairs of primer oligomers of the present invention (numbered SEQ ID No. 1-192, see Table 1) were synthesized by Bio-Industry, and the freeze-dried oligomers were completely resuspended in 1xTE to a concentration of 100 μM, and vortexed and centrifuged thoroughly. 5 uL of primers numbered SEQ ID No. 1-96 were added to a 1.5 mL Eppendorf tube labeled "Pool 1 (100 μM)", and the process was repeated for primers numbered SEQ ID No. 97-192 and labeled "Pool 2 (100 μM)", and the concentration of each primer pool was 100 μM.
[0069] Using molecular grade water, dilute 100 μM pools 1:10 to obtain a 10 μM concentration of primers.
[0070] Note: The final concentration of each primer is 15nM. For example, there are 96 primers in Pool 1 and 96 primers in Pool 2. Therefore, 3.6μL of primer pool (10μM) is required for each 25μL reaction (the total system of multiplex PCR reaction in the next step is 25uL). Prepare 100μL aliquots of 10μM primer dilutions and freeze to prevent degradation or contamination.
[0071] Calculation method: (15*96*25) / (10*1000)=3.6
[0072] (4) Multiplex PCR reaction:
[0073] In PCR tubes or plates, perform two PCR reactions for each sample with the following reaction systems:
[0074]
[0075] Add 2.5 μL of cDNA to each of the above PCR reactions, mix gently and centrifuge to collect the liquid at the bottom of the tube.
[0076] Note: Up to 5 μL of cDNA may be added to each PCR reaction to improve amplification of low concentration samples. Using 5 μL of cDNA will require a 20 μL cDNA reaction and may be more likely to cause inhibition, so use with caution.
[0077] Set up the following program on the thermal cycler:
[0078]
[0079] Note: Cycle number is 25 for Ct between 18-21 and up to 35 for Ct around 35. The calibration of the thermal cycler can vary between instruments. If you see amplicon 64 fall off, lower the annealing / extension temperature to 63°C. A denaturation temperature of 95°C can also be used and may slightly increase PCR yield.
[0080] (5) Purification of multiplex PCR products: The products of the above two reactions were combined into one EP tube and purified using AMPure XP magnetic beads. Both sides were rinsed with 200 ul of freshly prepared 80% anhydrous ethanol and then eluted with nuclease-free water to obtain the purified product.
[0081] (6) Quantification of multiple PCR products: The purified products were quantified using the Qubit dsDNA HS Assay Kit. The total amount of the target product obtained using the capture kit of the present invention is as follows: 150 ng for a Ct value of about 35, 200 ng for a Ct value of about 30, and 2000 ng for a Ct value of about 20.
[0082] (6) Library construction and sequencing: The purified products can be directly used for subsequent library construction and sequencing experiments, such as the second-generation Illumina sequencing or the third-generation portable nanopore gene sequencing platform developed by Qi Carbon.
[0083] Example 3 Library Construction
[0084] (1) Double-stranded DNA fragmentation: After the double-stranded DNA obtained by whole-genome capture is quantified by Qubit, 5ul (diluted to 0.2ng / ul, total 1ng) is taken; 10ul TD (Tagment DNA Buffer) is added to the corresponding well of the PCR plate and mixed by pipetting; 5ul ATM (Amplicon Tagment Mix) is added and mixed by pipetting; centrifuge at 20℃ and 280g for 1min; run the following program on a thermal cycler (reaction system: 20ul / well): hot cover at 100℃, 55℃ for 5min, and immediately add 5ul NT (Neutralize Tagment Buffer) after the temperature drops to 10℃; mix by pipetting; centrifuge at 280g for 1min; incubate at room temperature for 5min.
[0085] (2) Amplification of the library (adding adapters): Add 5ul of the forward adapter and 5ul of the reverse adapter to the above-mentioned fragmented double-stranded DNA; add 15ul of NPM (Nextera PCR Master Mix) to each sample well and mix by pipetting; centrifuge at 280g for 1min; run the following program on a thermal cycler (reaction system: 50ul / well, heated cover at 100°C):
[0086]
[0087] (Note: If you stop at this step, seal the PCR plate and store it at 2℃~8℃ for up to 2 days.)
[0088] (3) Purify the library: Purify the above product using AMPure XP magnetic beads, rinse both sides with 200ul of freshly prepared 80% anhydrous ethanol, and elute with nuclease-free water to obtain the purified product. (Note: If you stop at this step, seal the PCR plate and store it at -25℃ to -15℃. It can be stored for up to 7 days.)
[0089] Example 4 Next-generation sequencing of clinical samples
[0090] The kit provided by the present invention was used to test 4 samples to be tested, and the sequencing results were analyzed by the novel coronavirus whole genome analysis software. Each sample in the second-generation sequencing experiment generated about 700 to 1000 Mbp of sequencing data. The results showed that the amplification system achieved relatively uniform coverage of SARS-CoV-2, and all amplified regions achieved a coverage depth of >100 times. The sequencing results are as follows: Figure 1-4 As shown. Among them, the genome coverage of the site sequencing depth ≥30X is: 99.39% (samples with a Ct value of about 35), 99.53% or 99.35% (samples with a Ct value of about 30), 99.46% (samples with a Ct value of about 22), as shown in Table 2. The sequencing results of the present invention show that, under the premise of 700 to 1000 Mbp of available sequencing data, the genome coverage of the site sequencing depth ≥30X of the four samples to be tested is all above 99.35%, indicating that the non-specific amplification of our capture kit is reduced and the utilization rate of sequencing data is improved.
[0091] Table 2 Ct values of the four samples to be tested and the total amount of target fragments obtained using the capture reagent of the present invention and the genome coverage with site sequencing depth ≥30X
[0092]
[0093] Example 5: Third-generation sequencing of clinical samples
[0094] The primers in the kit provided by the present invention were used to capture the amplicons of the two samples to be tested (S2 and S4) in Example 4, and then the library was constructed and sequenced according to the QDL-E V1.1 library construction kit of Qi Carbon Technology and the QDS V1.1 sequencing kit of Qi Carbon Technology. The whole genome of SARS-COV-2 NC_045512 was used as the reference sequence, and bwa mem and minimap2 were used for alignment and splicing, and the phylogenetic tree was constructed according to the classification and identification algorithm freebayes of Pango lineage. Finally, the analysis report was obtained. Each sample in the three-generation sequencing experiment generated more than 100Mbp of sequencing data, and generated a total number of sequences of about 340,000 and 270,000, respectively. The results showed that the amplification system achieved relatively uniform coverage of SARS-CoV-2, and achieved a coverage depth of >100 times for all amplified regions. The sequencing results are as follows: Figure 5-6 Among them, the genome coverage of sites with sequencing depth ≥ 30X was 99.59% and 99.37%, respectively, as shown in Table 3.
[0095] Table 3 Total data volume, total number of sequences and genome coverage of sites with sequencing depth ≥ 30X obtained by using the capture reagent of the present invention for the three-generation sequencing of two samples to be tested
[0096]
[0097] Example 6 Mutation Detection
[0098] The capture kit of the present invention was used to detect a BA.2.86 sample (S5) with low sequencing coverage in the prior art. The second-generation sequencing results were analyzed by the novel coronavirus whole genome analysis software. The results are shown in Table 4. Figure 7 shown.
[0099] Comparative Example 1
[0100] The method consistent with Examples 1 to 6 was adopted, except that Fig. 9 The 98 pairs of capture primers shown in the figure, combined with an efficient reverse transcription system and a high-fidelity Tag enzyme amplification system, achieve whole genome amplification. The primer sequence information of this technology is as follows Fig. 9 The sequencing results are shown in Figure 8 shown.
[0101] Comparison of the experimental results of Example 6 and Comparative Example 1 shows that compared with Comparative Example 1 (prior art) (sequencing results as shown in Figure 8 As shown), compared with the kit according to the present invention (sequencing results as shown Figure 7The amplification system (as shown in Table 4) not only achieved relatively uniform coverage of SARS-CoV-2, but also improved the coverage of site sequencing depth ≥ 30X, and increased the total number of genomic nucleotide mutation sites, as shown in Table 4.
[0102] Table 4: Genome coverage and total number of genomic nucleotide mutation sites obtained by detecting BA.2.86 samples with a sequencing depth of ≥30X according to Example 6 and Comparative Example 1
[0103]
Claims
1. A composition for whole genome detection of a novel coronavirus, comprising: Oligonucleotides as shown in SEQ ID NOs: 1-192.
2. The composition according to claim 1, wherein Further included are primer pairs designed based on the sequencing adapter.
3. Use of the composition as described in claim 1 or 2 in the preparation of a kit for the detection of the whole genome of the new coronavirus.
4. A kit for whole genome detection of a novel coronavirus, comprising: The composition according to claim 1 or 2.
5. The kit according to claim 4, wherein It further comprises reagents required for fragmentation, preferably a DNA fragmentation enzyme.
6. The kit according to claim 4, wherein Further comprising a reagent for purifying the fragments, preferably magnetic beads.
7. A method for constructing a novel coronavirus whole genome gene library, the method comprising: 1) amplifying the BRCA1 / 2 gene in a sample using the composition according to claim 1 or 2, Obtaining an amplicon; 2) fragmenting the amplicon; 3) Purify the fragments, perform end repair and add adenylate; 4) Connect the joint; as well as 5) One or both of the second generation sequencing and the third generation sequencing.
8. The method according to claim 7, wherein: The fragmentation in step 2) is chemical fragmentation or physical fragmentation.
9. The method according to claim 7, wherein the purification of the fragments in step 3) is performed by adjusting the amount of the magnetic bead solution.
10. A novel coronavirus whole genome gene library obtained according to the method described in any one of claims 7 to 9.
